"Heterozygote" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An individual having different alleles at one or more loci regarding a specific character.
| Descriptor ID |
D006579
|
| MeSH Number(s) |
G05.380.383
|
| Concept/Terms |
Genetic Carriers- Genetic Carriers
- Carrier, Genetic
- Genetic Carrier
- Carriers, Genetic
|
Below are MeSH descriptors whose meaning is more general than "Heterozygote".
Below are MeSH descriptors whose meaning is more specific than "Heterozygote".
This graph shows the total number of publications written about "Heterozygote" by people in this website by year, and whether "Heterozygote" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 1 | 6 | 7 |
| 1997 | 0 | 3 | 3 |
| 1998 | 2 | 5 | 7 |
| 1999 | 2 | 3 | 5 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 9 | 9 |
| 2002 | 0 | 13 | 13 |
| 2003 | 1 | 9 | 10 |
| 2004 | 0 | 8 | 8 |
| 2005 | 1 | 6 | 7 |
| 2006 | 0 | 7 | 7 |
| 2007 | 0 | 6 | 6 |
| 2008 | 1 | 4 | 5 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 5 | 5 |
| 2011 | 7 | 10 | 17 |
| 2012 | 0 | 9 | 9 |
| 2013 | 1 | 12 | 13 |
| 2014 | 3 | 9 | 12 |
| 2015 | 2 | 14 | 16 |
| 2016 | 1 | 12 | 13 |
| 2017 | 0 | 13 | 13 |
| 2018 | 1 | 18 | 19 |
| 2019 | 1 | 5 | 6 |
| 2020 | 1 | 11 | 12 |
| 2021 | 3 | 4 | 7 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 4 | 4 |
| 2024 | 1 | 5 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heterozygote" by people in Profiles.
-
Causal interpretations of family GWAS in the presence of heterogeneous effects. Proc Natl Acad Sci U S A. 2024 Sep 17; 121(38):e2401379121.
-
Germline CDH1 Variants and Lifetime Cancer Risk. JAMA. 2024 09 03; 332(9):722-729.
-
Thr92Ala-DIO2 heterozygosity is associated with skeletal muscle mass and myosteatosis in patients with COVID-19. Eur Thyroid J. 2024 Aug 01; 13(4).
-
De novo variants in the RNU4-2 snRNA cause a frequent neurodevelopmental syndrome. Nature. 2024 Aug; 632(8026):832-840.
-
Peripheral T Cell Development and Immunophenotyping of Twins with Heterozygous FOXN1 Mutations. Immunohorizons. 2024 07 01; 8(7):492-499.
-
The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration. Cancer. 2024 Oct 01; 130(19):3297-3304.
-
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. Cancer Med. 2023 08; 12(15):16142-16162.
-
Insulin Deficiency From Insulin Gene Mutation Leads to Smaller Pancreas. Diabetes Care. 2023 04 01; 46(4):773-776.
-
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023 03 20; 41(9):1703-1713.
-
Refining Risk for Alzheimer's Disease Among Heterozygous APOE?4 Carriers. J Alzheimers Dis. 2023; 94(2):483-489.